SCHEMBL14965186

SCHEMBL14965186

OCCc1nc(Cl)c2c(-c3ccc(F)cc3)csc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
ALDH1A1 P00352 4/20 0.56
HPGD P15428 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
SIRT5 Q9NXA8 1/20 0.44
MAPT P10636 5/20 0.42
KMT2A Q03164 4/20 0.42
HTT P42858 2/20 0.42
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 2/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368799 0.80 LMNA (0.64) LMNASMN1; SMN2ALDH1A1HPGDRXFP1
SCHEMBL14965104 0.80 ALDH1A1 (0.48) LMNASMN1; SMN2ALDH1A1HPGDRXFP1
SCHEMBL3381310 0.79 ALDH1A1 (0.47) LMNASMN1; SMN2ALDH1A1HPGDRXFP1
SCHEMBL2368929 0.78 LMNA (0.61) LMNASMN1; SMN2ALDH1A1HPGDRXFP1
SCHEMBL16292993 0.77 ALDH1A1 (0.45) LMNASMN1; SMN2ALDH1A1HPGDRXFP1
SCHEMBL2368683 0.73 TNF (0.56) LMNASMN1; SMN2ALDH1A1MAPTCSNK2A2
SCHEMBL2368393 0.72 ALDH1A1 (0.56) LMNASMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL2368714 0.72 ESR1 (0.40) LMNASMN1; SMN2ALDH1A1HPGDRXFP1
SCHEMBL1604911 0.72 SMN1; SMN2 (1.00) LMNASMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL2369123 0.71 ALDH1A1 (0.55) LMNASMN1; SMN2ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2016-06-02 US disclosed
US-9290511-B2 Thieno-pyrimidines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2016-03-22 US disclosed
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2014-12-18 US disclosed
EP-2780343-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2014-09-24 EP disclosed
WO-2013072694-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors KCNA3, KCNJ1, KCNJ11 LMNA 3153/4885SMN1; SMN2 3639/4885ALDH1A1 1630/4885
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS KCNA3, KCNJ1, KCNJ11 LMNA 3254/4885SMN1; SMN2 3669/4885ALDH1A1 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.